This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Pharmaceutical detailing is the most time-tested marketing format in the medical content world. Old-timer sales reps should remember how pharmaceuticalcompanies reckoned face-to-face (F2F) visits with doctors as the most effective approach to achieving their sales targets. What is Pharmaceutical Detailing?
Any reduced availability of medicines has a significant impact on patientcare. As visibility diminishes, mismanagement of the supply chain can not only lead to revenue and reputational damage for manufacturers but more importantly, loss of life for patients. The CMO solution.
Generic and biosimilar pharmaceuticalcompany and Novartis subsidiary Sandoz announced its plan to accelerate patient access to biosimilars. In a 15 June statement, Sandoz said that it hoped the Act4Biosimilars action plan will provide actionable solutions to overcome barriers preventing patient access to biosimilars.
These improvements enable 5G networks to reduce download and upload times, enhance reliability, and provide stronger connectivity. PharmaceuticalcompaniesPharmaceuticalcompanies can transform their approaches to clinical trials with the help of 5G networks.
Barry DeCoster, PhD, an associate professor of bioethics at the University of Michigan, describes gender affirming care as “safe and effective” for most patients. Most drugs used here are prescribed off-label, and experts say pharmaceuticalcompanies remain hesitant to conduct clinical trials studying gender-affirming care.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content